Product information
Slides on OPDUALAG MoA
All reimbursed indications for OPDIVO, OPDIVO + YERVOY and OPDUALAG in melanoma
NEW
Understanding the anti-tumor
immune response
NEW
Nivolumab to restore the anti-
tumor immune response
NEW
Combining nivolumab and
relatlimab to enhance the anti-
tumor immunity
NEW
Combining nivolumab and
ipilimumab to enhance the anti-
tumor immunity
Practical user guide
based on OPDIVO
and OPDUALAG SmPC
Dosing scheme OPDIVO,
OPDIVO+YERVOY, OPDUALAG
in advanced melanoma
PD-L1 Testing
overview for BMS assets
Expert opinion
NEW
Prof. Baurain on 10-year follow-up of Opdivo+Yervoy in 1L advanced melanoma (CM-067)
NEW
Prof. Neyns on 10-year follow-up of Opdivo+Yervoy in 1L advanced melanoma (CM-067).
BMS satellite symposium
Traps of PD-L1 scoring
in advanced melanoma
A library of patient
cases treated with
OPDIVO+YERVOY in 1L melanoma
Patient & nurse materials
A diary for your patients
treated with
OPDUALAG
A diary for your patients
treated with OPDIVO + YERVOY
www.immunooncology.be
An educational website
on immunotherapy for your
nurses and your patients
Patient brochure
with practical information
on immunotherapy
Patient alert card
OPDIVO
Patient alert card
OPDUALAG
